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M onitoring the treatment response in cancer patients is crucial to making decisions regard-
ing further treatment.  Currently,  the accepted standard 
for assessing responses to therapy involves the use of 
objective response criteria,  including computed tomog-
raphy (CT) findings (Response Evaluation Criteria in 
Solid Tumors [RECIST]) [1].  However,  the RECIST 1.1 
criteria have certain limitations,  especially with respect 
to assessment of the therapy response in bone [1 , 2].
Functional imaging modalities such as positron 
emission tomography (PET) represent an innovative 
approach for assessment of the therapy response.  For 
example,  PET/CT with fluorodeoxyglucose has been 
shown to detect therapeutic effects in cases with a num-
ber of different tumor entities earlier and more precisely 
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We investigated the effectiveness of 11C-choline-positron emission tomography/computed tomography (PET/
CT) for evaluating treatment response in patients with prostate cancer or renal cell carcinoma.  We performed 
34 11C-choline PET/CT scans before/after a combined total of 17 courses of treatment in 6 patients with prostate 
cancer and 2 with renal cell carcinoma.  The 17 treatments including hormonal therapy,  radiotherapy,  chemo-
therapy,  radium-223,  molecular target therapy,  radiofrequency ablation,  transcatheter arterial embolization,  
and cancer immunotherapy yielded 1 (5.9%) complete metabolic response (CMR),  3 (17.6%) partial metabolic 
responses (PMRs),  2 (11.8%) stable metabolic diseases (SMDs),  and 11 (64.7%) progressive metabolic diseases 
(PMDs).  Target lesions were observed in bone (n = 14),  lymph nodes (n = 5),  lung (n = 2),  prostate (n = 2),  and 
pleura (n = 1),  with CMR in 4,  PMR in 10,  SMD in 8 and PMD in 2 lesions.  SUVmax values of the target 
lesions before and after treatment were 7.87 ± 2.67 and 5.29 ± 3.98,  respectively,  for a mean reduction of 
−35.4 ± 43.6%.  The response for the 8 prostate cancer-treatment courses was PMD,  which correlated well with 
changes in serum prostatic specific antigen (PSA) (7 of 8 cases showed increased PSA).  11C-choline-PET/CT 
may be an effective tool for detecting viable residual tumors and evaluating treatment response in prostate can-
cer and renal cell carcinoma patients.
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than conventional imaging methods [3 , 4].  Also,  PET/
CT with 11C-choline or 18F-fluorocholine has emerged as 
a useful tool for investigating patients with prostate can-
cer because of its ability to show the site of tumor recur-
rence earlier than other imaging methods in a single 
examination [5-7],  and a recent paper showed the 
results of choline PET/CT for staging and restaging 
renal cell carcinoma [8].  However,  few studies have 
evaluated the use of choline PET/CT for the assessment 
of treatment response in patients with prostate cancer 
[9-12] or renal cell carcinoma [13].  Therefore,  the use-
fulness of choline PET/CT for evaluating treatment 
responses in such cases has yet to be clarified.
In the present study,  we investigated the role of 
11C-choline PET/CT in the evaluation of the response to 
various treatments in patients with prostate cancer and 
renal cell carcinoma.
Materials and Methods
Patients. This prospective study was approved by 
the ethics committee of our institution (approval no. 
2213).  Informed consent was obtained from each 
patient after a full explanation of the procedure details.  
From January 2016 to May 2018,  a total of 8 patients 
(age range 44-79 years,  median 62.4 years) — 6 males 
with prostate cancer and 2 females with renal cell clear 
cell carcinoma — underwent a total of 34 11C-choline 
PET/CT scans before and after 17 courses of treatment,  
including molecular target therapy (n = 3),  hormonal 
therapy (n = 3),  molecular target and radiation therapy 
(n = 2),  hormonal and radiation therapy (n = 2),  
radium-223 therapy (n = 2),  chemotherapy (n = 1),  
radiation therapy (n=1),  cancer immunotherapy (n=1),  
radiofrequency ablation and molecular target therapy 
(n = 1),  and transcatheter arterial embolization and 
molecular target therapy (n = 1) (Tables 1 , 2).
11C-choline PET/CT. 11C-choline was synthesized 
using a commercial module,  as described by Hara [14],  
using a CYPRIS-325R cyclotron (Sumitomo Heavy 
Industries [SHI],  Tokyo).  Acquisition of emission 
scans from the mid-thigh to head was started approxi-
mately 6 minutes after the intravenous injection of 
11C-choline at 3.0 MBq/kg body weight.  All PET/CT 
examinations were performed using a PET/CT scanner 
equipped with a 64-multi-detector CT device (Gemini 
TF64; Philips Medical Systems,  Eindhoven,  the 
Netherlands).  Whole-body PET acquisition in 3D 
mode was performed from the mid-thigh to the top of 
the head (1.5 min per bed position,  6-8 bed positions) 
and reconstructed using the ordered-subset expectation 
maximization reconstruction algorithm (33 subsets,  3 
iterations,  4 mm per slice),  with attenuation correction 
based on low-dose CT (120 kVp,  100 mA,  slice thick-
ness 2 mm,  transverse field of view 600 mm),  which 
was also used for anatomical correlation.
Image analysis. Two experienced readers,  each 
with 3 years of experience with 11C-choline PET/CT 
and no knowledge of other imaging or clinicopatholog-
ical results,  interpreted all of the obtained 11C-choline 
PET/CT images,  with decisions based on consensus.  
Semiquantitative analysis of abnormal radiotracer 
uptake for each lesion was also performed using 
SUVmax,  which was defined as the highest SUV value 
for pixels with the highest count within the volume of 
interest (VOI).  Here,  SUV was defined as VOI radioac-
tivity concentration (Bq/mL)/[injected dose (Bq)/
patient weight (g)].  Values were determined for focal 
areas of uptake and recorded.
Tumor response assessment. Post-treatment 
11C-choline PET/CT findings were compared with base-
line PET findings to assess the imaging response to 
treatment according to the European Organization for 
Research Treatment of Cancer (EORTC) criteria [3],  as 
noted in previous reports [9-12].  The appearance of a 
new PET-positive lesion in the second PET examina-
tion was considered to represent progressive metabolic 
disease (PMD).  An SUVmax increase of < 25% or a 
decrease of < 25% for previously noted lesions without 
additional lesion development was considered to be 
stable metabolic disease (SMD),  while an SUVmax 
decrease of ≥ 25% for previously noted lesions in the 
second PET in relation to the first PET examination 
without additional lesion development was considered 
to be a partial metabolic response (PMR).  Second PET 
scan findings that were negative with no pathological 
choline uptake were considered to represent a complete 
metabolic response (CMR).  When diffuse metastatic 
disease spread (> 10 lesions) was seen,  SUVmax was 
determined for the 10 lesions with the highest level of 
uptake.
Statistical analysis. The final diagnosis was 
obtained based on radiological imaging findings or clin-
ical follow-up results,  including serum prostatic specific 
antigen (PSA) level,  MRI,  CT,  bone scintigraphy,  and 
11C-choline PET/CT findings.  For comparisons of two 
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groups,  a non-parametric test was used.  SAS,  version 
9.3 (SAS Institute,  Cary,  NC,  USA),  was used for the 
statistical analysis,  with a value of P < 0.05 considered to 
be significant.
Results
Of the 17 treatment courses analyzed,  CMR,  PMR,  
SMD,  and PMD,  as determined by the EORTEC crite-
ria,  were seen in 1 (5.9%),  3 (17.6%),  2 (11.8%),  and 
11 (64.7%) cases,  respectively (Tables 1 , 2).  Target 
lesions were observed in a total of 24 regions,  including 
bone (n = 14),  lymph nodes (n = 5),  lung (n = 2),  pros-
tate (n = 2),  and pleura (n = 1),  with CMR,  PMR,  
SMD,  and PMD shown in 4 , 10 , 8,  and 2,  respectively 
Figs. 1 , 2.  The mean SUVmax values of the target 
lesions before and after treatment were 7.87 ± 2.67 
(2.82-15.03) and 5.29 ± 3.98 (0-16.16),  respectively,  for 
a mean reduction of −35.4 ± 43.6% (−100% to 65.5%).
Lymph nodal metastases in 5 cases,  lung metastases 
in 2 cases,  and pleura metastases in 1 case were mea-
surable by the CT part of PET/CT.  The mean reduction 
rate of size and SUVmax in 8 cases were −34.8 ± 31.4% 
(range −100 to 0%) and −56.3± 25.1% (−100 to −21.5%),  
respectively (Tables 1 , 2).  The reduction rate of SUVmax 
was higher than that of size without a significant differ-
ence (p = 0.56).  CR/PR/SD was seen in 1/4/3 patients 
with RECIST,  while CMR/PMR/SMD was seen in 
1/6/2 patients with PERCIST,  respectively.
The 6 patients with prostate cancer underwent a 
total of 16 11C-choline PET/CT scans before and after 8 
different types of treatment courses.  The response to all 
8 treatment types was PMD and corresponded well with 
changes in the serum PSA level (7 of 8 cases showed an 
increasing PSA level).
Discussion
In this series with a small cohort,  11C-choline PET/
CT was shown to be useful for detecting viable residual 
tumors and evaluating the treatment response in 
patients with prostate cancer and renal cell carcinoma.  
In the prostate cancer patients,  the treatment response 
by 11C-choline PET was well correlated with serum 
PSA.  In the measurable lesions (most renal cell carci-
nomas),  11C-choline PET/CT tended to show a better 
treatment response than CT.
Several previous studies evaluated choline PET/CT 
findings for their usefulness in assessing treatment 
responses in patients with prostate cancer [9-12].  In one 
of these studies,  Ceci et al.  [9] investigated the role of 
11C-choline PET/CT in evaluating the response to 
docetaxel in 61 cases with metastatic castration-resis-
tant prostate cancer and compared the radiologic 
response evaluated using 11C-choline PET/CT to the 
PSA response.  Disease progression was defined as the 
appearance of a new PET-positive lesion,  while 
response after chemotherapy was defined as a decrease 
in the PSA level greater than or equal to 50%.  
Radiologic disease progression was observed in 44% of 
patients with a PSA response.  Moreover,  a higher 
tumor burden,  expressed as > 10 PET-positive bone 
lesions prior to docetaxel treatment,  was significantly 
associated with an increased probability of disease pro-
gression.  More recently,  a new generation of hormonal 
therapy drugs,  such as abiraterone and enzalutamide,  
has become available for patients who develop castra-
tion-resistant prostate cancer,  with good results shown 
in terms of biochemical response and pharmacologic 
effects.  De Giorgi et al.  [10 , 11] assessed the usefulness 
of 18F-choline PET/CT for evaluating metastatic castra-
tion-resistant prostate cancer patients with regard to 
their early response to treatment with abiraterone 
(n = 43) or enzalutamide (n = 36).  The authors con-
cluded that a radiologic response,  assessed using 
18F-choline PET/ CT findings,  was associated with more 
favorable overall survival than a PSA response greater 
than or equal to 50% alone.  Maines et al.  [12] evaluated 
the role of 18F-choline PET/CT in monitoring the 
response to enzalutamide in 30 patients with metastatic 
castration-resistant prostate cancer.  They noted that 
SUVmax determined by PET prior to enzalutamide 
treatment was significantly related to biochemical 
recurrence-free,  radiologic progression-free,  and over-
all survival rates.  In comparison with these previous 
reports [9-12],  our series had limitations: namely,  the 
number of prostate patients was relatively small and the 
therapy for prostate cancer was not uniform.
Middendorp et al.  [13] reported that response eval-
uation based on 18F-choline PET/CT results after tyro-
sine kinase inhibitor treatment was effective in 2 renal 
cell carcinoma patients.  Our series included a larger 
number of renal cell carcinoma cases and various ther-
apies.  PMR/PMD was seen in 1/1 patients in the report 
of Middendorp et al.  [13],  while CMR/PMR/SMD/
PMD were seen in 1/3/2/3 cases in our study,  respec-
344 ?????? ???????? ????????? ????????????? ???? ???? ??
tively.  Because there are no useful serum markers in 
renal cell carcinoma comparable to PSA in prostate 
cancer,  choline PET/CT can be an important tool for 
assessing the response to treatment in renal cell carci-
noma.
In conclusion,  we consider that choline PET/CiT 
provides additional information regarding the extent of 
active disease,  particularly in regard to the sites and 
number of active lesions in patients with prostate cancer 
or renal cell carcinoma.  Thus,  assessment of the ther-
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???? ?　 Representative case of a 44-year-old woman with renal cell carcinoma after surgery for the primary tumor,  molecular target ther-
apy,  and radiation therapy of mediastinal lymph node recurrence and lumbar L4 vertebra bone metastasis.  A,  Maximum intensity projec-
tion (MIP) from baseline 11C-choline PET/CT shows two abnormal 11C-choline uptakes in the mediastinum and lumbar spine (arrows); B,  
MIP from 11C-choline PET/CT after radiofrequency ablation and molecular target therapy shows disappearance of two abnormal 11C-choline 
uptakes,  reﬂecting a complete metabolic response (CMR); C,  Baseline 11C-choline PET/CT and CT show strong 11C-choline uptake (max-
imum standardized uptake value (SUVmax),  8.41) and sclerosing change of L4 vertebra (arrow),  suggesting recurrence of bone metasta-
sis; D,  11C-choline PET/CT and CT after radiofrequency ablation and molecular target therapy show disappearance of the abnormal 
11C-choline uptake (arrow),  suggesting viable tumor disappearance (CMR); E,  Baseline 11C-choline PET/CT and CT show mild 11C-choline 
uptake (SUVmax,  3.7) and a small mediastinal lymph node measuring 6×9 mm (arrow),  suggesting recurrence of lymph node metastasis;  
F,  11C-choline PET/CT and CT after molecular target therapy show disappearance of the abnormal 11C-choline uptake (arrow),  suggesting 
viable tumor disappearance (CMR).
apy response using choline PET/CT may enable more 
tailored treatment approaches,  possibly leading to 
increased survival and improved quality of life.  
However,  our cohort was small,  and a larger prospec-
tive study is necessary to further explore and validate 
the potential of choline PET/CT for monitoring the 
treatment response in prostate cancer and renal cell 
carcinoma patients.
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Ａ Ｂ Ｃ
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Ｅ
Ｆ
Ｇ
Ｈ
???? ?　 Representative case of a 79-year-old woman with prostate cancer treated by hormonal therapy.  A,  MIP from baseline 11C-choline 
PET/CT shows two abnormal 11C-choline uptakes in the pelvis (arrows); B,  MIP from 11C-choline PET/CT after radiation therapy and hor-
monal therapy shows multiple abnormal 11C-choline uptakes in the pelvis and abdomen (arrows),  reﬂecting progressive metabolic disease 
(PMD); C,  Baseline 11C-choline PET/CT and CT show intense 11C-choline uptake (SUVmax,  8.27) in the prostate (arrow),  suggesting 
viable residual primary cancer; D,  11C-choline PET/CT and CT after radiation therapy and hormonal therapy show decreases in the abnor-
mal 11C-choline uptakes (SUVmax,  4.09) in the prostate (arrow),  suggesting decreased tumor viability (partial metabolic response 
(PMR)); E,  Baseline 11C-choline PET/CT and CT show intense 11C-choline uptake (SUVmax,  9.54) and swollen left internal iliac lymph 
node measuring 25×35 mm (arrow),  suggesting viable residual lymph node metastasis; F,  11C-choline PET/CT and CT after radiation 
therapy and hormonal therapy show decreases in the abnormal 11C-choline uptake (SUVmax,  5.38) and size (8×12 mm) (arrow),  suggest-
ing decreased tumor viability (PMR); G,  Baseline 11C-choline PET/CT and CT on this slice show no abnormal ﬁndings; H,  11C-choline 
PET/CT and CT after radiation therapy and hormonal therapy on the same slice as in G show the appearance of two para-aortic lymph 
nodes with abnormal 11C-choline uptakes (arrows),  suggesting new lymph node recurrence (PMD).
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